Mustang Bio IncNASDAQ:MBIONASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.2800
- TODAY'S CHANGE (%)-0.0135 (-4.5997%)
- Bid / Lots0.2800/ 5
- Ask / Lots0.2847/ 22
- Open / Previous Close0.2890 / 0.2935
- Day Range
- 52 Week Range
- Volume3,194,118
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MBIO |
|---|---|---|
| 09:32 ET | 38588 | 0.2891 |
| 09:34 ET | 28972 | 0.2801 |
| 09:36 ET | 2967 | 0.28505 |
| 09:38 ET | 1300 | 0.2803 |
| 09:39 ET | 11000 | 0.2803 |
| 09:41 ET | 18256 | 0.2803 |
| 09:43 ET | 3524 | 0.282417 |
| 09:45 ET | 24840 | 0.2846 |
| 09:48 ET | 1994 | 0.285962 |
| 09:50 ET | 8700 | 0.2879 |
| 09:52 ET | 19515 | 0.2968 |
| 09:54 ET | 15579 | 0.2949 |
| 09:56 ET | 10000 | 0.2933 |
| 09:57 ET | 7000 | 0.29335 |
| 09:59 ET | 3681 | 0.295 |
| 10:01 ET | 35625 | 0.2934 |
| 10:03 ET | 5994 | 0.2967 |
| 10:06 ET | 9200 | 0.2935 |
| 10:08 ET | 91350 | 0.307291 |
| 10:10 ET | 39193 | 0.3098 |
| 10:12 ET | 34579 | 0.3073 |
| 10:14 ET | 75274 | 0.3198 |
| 10:15 ET | 34794 | 0.3151 |
| 10:17 ET | 124525 | 0.32 |
| 10:19 ET | 225638 | 0.3301 |
| 10:21 ET | 161348 | 0.3201 |
| 10:24 ET | 42300 | 0.326 |
| 10:26 ET | 132786 | 0.3116 |
| 10:28 ET | 42830 | 0.31645 |
| 10:30 ET | 6958 | 0.3181 |
| 10:32 ET | 33637 | 0.319 |
| 10:33 ET | 24796 | 0.319 |
| 10:35 ET | 154129 | 0.3206 |
| 10:37 ET | 3600 | 0.3217 |
| 10:39 ET | 5400 | 0.3244 |
| 10:42 ET | 98324 | 0.3245 |
| 10:44 ET | 2766 | 0.3239 |
| 10:46 ET | 55441 | 0.3288 |
| 10:48 ET | 194290 | 0.3265 |
| 10:50 ET | 8818 | 0.3278 |
| 10:51 ET | 100601 | 0.3139 |
| 10:53 ET | 27776 | 0.322201 |
| 10:55 ET | 10753 | 0.32 |
| 10:57 ET | 37315 | 0.3219 |
| 11:00 ET | 25907 | 0.3219 |
| 11:02 ET | 7353 | 0.321699 |
| 11:04 ET | 96404 | 0.32 |
| 11:06 ET | 800 | 0.32 |
| 11:08 ET | 4354 | 0.316 |
| 11:09 ET | 82978 | 0.305347 |
| 11:11 ET | 9545 | 0.3011 |
| 11:13 ET | 25831 | 0.30706 |
| 11:15 ET | 500 | 0.3053 |
| 11:18 ET | 210 | 0.3055 |
| 11:20 ET | 9730 | 0.3099 |
| 11:22 ET | 6600 | 0.306 |
| 11:24 ET | 911 | 0.3007 |
| 11:26 ET | 18544 | 0.3007 |
| 11:27 ET | 23600 | 0.3005 |
| 11:29 ET | 11313 | 0.3005 |
| 11:31 ET | 9173 | 0.2983 |
| 11:33 ET | 10875 | 0.3 |
| 11:36 ET | 6511 | 0.3037 |
| 11:38 ET | 74760 | 0.2989 |
| 11:40 ET | 1650 | 0.3 |
| 11:42 ET | 5800 | 0.3 |
| 11:44 ET | 12236 | 0.3 |
| 11:47 ET | 1186 | 0.3038 |
| 11:49 ET | 5145 | 0.302817 |
| 11:51 ET | 1508 | 0.302346 |
| 11:54 ET | 27146 | 0.3037 |
| 11:56 ET | 3000 | 0.3 |
| 11:58 ET | 4000 | 0.2982 |
| 12:00 ET | 1500 | 0.3 |
| 12:02 ET | 27520 | 0.295701 |
| 12:03 ET | 1150 | 0.2957 |
| 12:05 ET | 42733 | 0.2889 |
| 12:07 ET | 10073 | 0.2875 |
| 12:09 ET | 252097 | 0.2671 |
| 12:12 ET | 15992 | 0.2761 |
| 12:14 ET | 10900 | 0.276 |
| 12:16 ET | 8053 | 0.285 |
| 12:20 ET | 7700 | 0.281 |
| 12:23 ET | 12493 | 0.285 |
| 12:27 ET | 450 | 0.2825 |
| 12:30 ET | 16548 | 0.28 |
| 12:32 ET | 10311 | 0.2806 |
| 12:34 ET | 540 | 0.280729 |
| 12:36 ET | 100 | 0.28 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mustang Bio Inc | 10.9M | -0.1x | --- |
Curative Biotechnology Inc | 10.8M | -1.1x | --- |
Carmell Corp | 10.8M | -0.3x | --- |
Vincerx Pharma Inc | 11.2M | -0.3x | --- |
Transcode Therapeutics Inc | 10.6M | 0.0x | --- |
Kazia Therapeutics Ltd | 16.7M | -0.7x | --- |
Company Information
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Its pipeline is focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. It is developing a CAR T therapy for hematologic malignancies in partnership with Fred Hutch targeting CD20 (MB-106). In partnership with St. Jude, its X-linked Severe Combined Immunodeficiency (XSCID) gene therapy programs (MB-117 and MB-217) are being developed under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition.
Contact Information
- Headquarters
- 377 PLANTATION STREETWORCESTER, MA, United States 01605
- Phone
- 781-652-4500
- Fax
- 302-531-3150
Executives
- Executive Chairman of the Board
- Michael Weiss
- President, Chief Executive Officer, Director
- Manuel Litchman
- Interim Chief Financial Officer
- James Murphy
- Director
- Lindsay Rosenwald
- Independent Director
- Adam Chill
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 37.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.97 |
EPS | $-2.91 |
Book Value | $0.01 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
